69
Participants
Start Date
November 19, 2020
Primary Completion Date
August 3, 2023
Study Completion Date
August 10, 2023
Etripamil
The formulation of etripamil nasal spray consists of MSP-2017 (etripamil), water, acetic acid, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid. The dose of etripamil to be evaluated in this study is 70 mg.
Placebo
The formulation of placebo nasal spray consists of water, sodium acetate, disodium, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid to reproduce the same pH as the etripamil formulation.
QEII HSC - Nova Scotia Health Authority, Halifax
Hamilton Health Science, Hamilton
PACE (Partners in Advanced Cardiac Evaluation), Newmarket
Ottawa Hospital General & Civic Campus Research Institute, Ottawa
Institut de Cardiologie de Montreal, Montreal
CHU Montréal, Montreal
CIUSSS du Nord-de-l'Île-de-Montréal - Hôpital du Sacré-Cœur, Montreal
CISSS Bas-Saint-Laurent / Hôpital de Rimouski, Rimouski
CISSS des Laurentides / Unité de recherche clinique, Saint-Jérôme
CIUSSS de l'Estrie - CHU, Sherbrooke
CISSS de Lanaudière - Hôpital Pierre-Le Gardeur, Terrebonne
Jeroen Bosch Ziekenhuis, 's-Hertogenbosch
Jeroen Bosch Ziekenhuis Rijnstate Ziekenhuis, Arnhem
Slingeland Ziekenhuis, Doetinchem
Treant Zorggroep, Emmen
Elkerliek Ziekenhuis, Helmond
Franciscus Gasthuis, Rotterdam
Gelre Ziekenhuizen, Zutphen
Lead Sponsor
Collaborators (1)
The Montreal Health Innovations Coordinating Center (MHICC)
OTHER
JSS Medical Research Inc.
INDUSTRY
Milestone Pharmaceuticals Inc.
OTHER